摘要
In a recently published article in Science,Zak et al.discovered that the Janus kinase(JAK)inhibitor ruxolitinib alters innate and adaptive immune cells to an unanticipated,predominantly immune-stimulatory phenotype in mouse infection models.1 This finding motivated a clinical study,which showed that ruxolitinib treatment in combination with the anti-PD1 immune checkpoint inhibitor(ICI)nivolumab in a cohort of relapsed or refractory Hodgkin lymphoma(HL)patients demonstrated promising responses.
基金
Own work on HL is funded by the Deutsche Forschungsgemeinschaft(SFB 1530,C01)
Open access funding enabled and organized through project DEAL.
